Please login to the form below

Not currently logged in

Kirsti Gjellan swaps Pfizer for Sobi

Takes up role as senior VP manufacturing operations at Swedish Orphan Biovitrum

Sobi Kirsti GjellanSwedish Orphan Biovitrum (Sobi) has appointed Pfizer's Kirsti Gjellan as senior VP manufacturing operations.

Sobi gains an experienced mind with Gjellan, who most recently serving as managing director for Pfizer in Sweden as well as site leader for its plant in Strängnäs.

The site opened in 2009 to produce the active ingredients for growth hormone Genotropin (somatropin) and the acromegaly treatment Somavert (pegvisomant).

Gjellan spent nine years at Pfizer in total, during which time she received the John Mitchell Quality Award for quality in manufacturing in 2006 and the Swedish Change Management Award for the best Change Management Project in 2013.

Her previous experience includes a 16-year period at AstraZeneca where she worked across drug discovery, research and manufacturing.

Geoffrey McDonough, president and CEO at Sobi, said he was “delighted” to welcome Gjellan to the company.

"Kirsti will continue to build on the legacy of our biologics manufacturing organisation, and to prepare us for our future products for patients with rare diseases.

Gjellan will complete her move to Sobi in September this year when current senior VP manufacturing operations Lena Nyström is due to retire.

28th May 2014

From: Sales



Featured jobs

Subscribe to our email news alerts


Add my company
Four Health Media

Four Health Media creates world class integrated media solutions with global reach, deep insight, innovative methods and a highly personal...

Latest intelligence

How to get rep buy-in for multi-channel
How do you manage a team who may be resistant to change?...
Blog: Digital therapeutics: within our reach?
Digital therapeutics is a hot topic right now. By using digital technology to manage, treat or even prevent chronic conditions, digital therapeutics is promising to revolutionise healthcare. But is this...
figure 1
The valuable brand
Creating value beyond the pill is both possible and increasingly necessary...